Emerging and Investigational Probes

1 B Vitamin Supplementation

B vitamins are cofactors at specific points in energy metabolism and neurotransmitter synthesis. Which B vitamin produces a response points toward which metabolic bottleneck was rate-limiting: B1 (thiamine) → PDH/TCA; B2 (riboflavin) → Complex II; B3 (niacin) → the NAD+ pool; B6/P5P → neurotransmitter synthesis or BH4 recycling; B9/B12 → the methylation cycle, homocysteine burden, and BH4 recycling.

1.1 If B vitamins work

Finding: B1 response implicates the PDH/TCA bottleneck

If thiamine helps, pyruvate dehydrogenase or TCA-cycle entry was rate-limiting.

Certainty: Low to Medium.
Does NOT tell us: whether the deficit is dietary or consumption-driven.
Action: Supports thiamine repletion; investigate PDH/TCA flux.
Level of action: Partial root cause.

Finding: B2 response implicates Complex II

If riboflavin helps, the flavin-dependent Complex II step of the respiratory chain was limiting.

Certainty: Low to Medium.
Does NOT tell us: whether the limitation is enzymatic or cofactor-driven.
Action: Supports riboflavin repletion.
Level of action: Partial root cause.

Finding: B3 response implicates the NAD+ pool

If niacin helps, a depleted NAD+ pool was constraining redox reactions and energy transfer.

Certainty: Low to Medium.
Does NOT tell us: the cause of NAD+ depletion (consumption vs. synthesis).
Action: Supports NAD+ pool support.
Level of action: Partial root cause.

Finding: B6/P5P response implicates neurotransmitter synthesis or BH4 recycling

If P5P helps (e.g., increasing the GABA:Glx ratio, suggesting GAD impairment), neurotransmitter synthesis or BH4 recycling was cofactor-limited.

Certainty: Low to Medium.
Does NOT tell us: which neurotransmitter pathway is most affected.
Action: Supports P5P repletion; watch for sensory side effects.
Level of action: Partial root cause.

Finding: B9/B12 response implicates the methylation cycle

If folate/B12 helps, the methylation cycle, homocysteine handling, or BH4 recycling was limited.

Certainty: Low to Medium.
Does NOT tell us: whether an MTHFR variant or acquired depletion is responsible.
Action: Supports methylated-form repletion; check homocysteine and MTHFR.
Level of action: Partial root cause.

1.2 What a positive response does NOT reveal

Whether the deficiency is dietary or consumption-driven (inflammation consuming B6/BH4).
Whether correcting the cofactor removes the underlying consumer.

1.3 If B vitamins do NOT work

Inflammatory consumption may exceed supplementation capacity.
The cofactor deficiency may not be the rate-limiting step.
The wrong B vitamin may have been used for the specific bottleneck.

1.4 Key caveat

B6 at doses above 100 mg/day can cause peripheral neuropathy. Methylcobalamin and methylfolate are the preferred forms. If P5P worsens sensory symptoms, lower the dose.

1.5 How B vitamins combine with other medications

B vitamins + mitochondrial supplements both work → cofactor plus substrate co-depletion.
B vitamins work + inflammation markers remain elevated → inflammatory consumption continues; supplementation is compensatory only.
B6 works + LDA also benefits → shared BH4 recycling pathway (both dopamine synthesis and BH4 depend on B6).

1.6 Compendium

The full pharmacodiagnostic entries for individual B vitamins — including mechanism-exclusion logic, dose-specific side-effect diagnostic patterns, combination diagnostics, and worsening risk profiles — are at Mechanistic Cascade Tracing: From Hypothesis to Clinical Probe (sec-12, individual entries: Thiamine (B1), Niacin, Vitamin B12).

2 Dornase Alfa (Pulmozyme)

Recombinant DNase I that cleaves neutrophil extracellular traps (NETs) — webs of extruded DNA released by neutrophils. It probes whether excessive NETosis contributes, and whether a NET/DNase imbalance is accessible to enzymatic clearance.

2.1 If dornase alfa works

Finding: NETosis confirmed (if NET markers fall)

If NET biomarkers (cell-free DNA, MPO-DNA complexes, citrullinated histone H3) fall, a NET/DNase imbalance is confirmed and the NETs were accessible to clearance.

Certainty: Low to Medium.
Does NOT tell us: whether clearing NETs reverses downstream damage.
Action: Supports measuring NET biomarkers before and after; targets NETosis.
Level of action: Partial root cause.

Finding: Tissue-sequestered NETs (if markers unchanged despite trial)

If markers do not change, NETs may be sequestered in tissue and inaccessible to the enzyme in circulation.

Certainty: Low to Medium — inferential.
Does NOT tell us: where the sequestered NETs reside.
Action: Points toward a delivery problem rather than absence of NETosis.
Level of action: Partial root cause (diagnostic).

2.2 What a positive response does NOT reveal

Whether clearing NETs reverses downstream microthrombi or endothelial injury.
Whether NETosis is primary or secondary to an upstream trigger.

2.3 If dornase alfa does NOT work

NETs may not be the mechanism.
NETs may be tissue-sequestered and inaccessible.
NETosis may be present but not causing symptoms.

2.4 Key caveat

This is investigational — measure NET biomarkers before and after to assess biological response, not just symptoms. Inhaled dornase alfa targets pulmonary NETs; systemic delivery for vascular NETs may require a different approach.

2.5 How dornase alfa combines with other medications

Dornase alfa reduces markers + symptoms lag → NETs cleared but downstream damage (microthrombi, endothelial injury) persists.
Dornase alfa + NAC both work → an oxidative-stress → NETosis cascade; ROS drives NET formation, and NAC reduces the upstream ROS.

2.6 Compendium

The full pharmacodiagnostic entry — including mechanism-exclusion logic, dose-specific side-effect diagnostic patterns, combination diagnostics, and worsening risk profiles — is at Mechanistic Cascade Tracing: From Hypothesis to Clinical Probe (sec-12, Dornase alfa entry).

3 Fluvoxamine

At low doses, fluvoxamine is a sigma-1 receptor (S1R) agonist. S1R is an endoplasmic reticulum (ER) chaperone that regulates calcium signaling at mitochondria-associated membranes and modulates the integrated stress response (ISR). Low-dose fluvoxamine therefore probes ER-mitochondrial calcium dysregulation and ISR involvement, separate from its antidepressant (SSRI) action.

3.1 If fluvoxamine works

Finding: S1R agonism reduces ER-mitochondrial calcium dysregulation or ISR activity

If benefit occurs at doses below the antidepressant range (25–50 mg), the mechanism is S1R agonism rather than serotonin reuptake inhibition — implicating ER stress or disrupted ER-mitochondrial calcium transfer.

Certainty: 0.40 — case reports only.
Does NOT tell us: which arm of the ER stress response is affected.
Action: Supports ER-mitochondrial calcium/ISR involvement; low dose distinguishes S1R from SSRI action.
Level of action: Partial root cause.

3.2 What a positive response does NOT reveal

Whether the benefit is truly S1R-mediated or a low-dose serotonergic effect.
Which UPR/ISR branch is involved.

3.3 If fluvoxamine does NOT work

ER stress may not be a dominant mechanism.
SSRI-class side effects may confound assessment of benefit.
Fluvoxamine strongly inhibits CYP2D6 and CYP1A2 — elevated plasma levels of co-administered drugs may cause adverse effects that mask benefit.

3.4 Key caveat

Fluvoxamine is the strongest CYP1A2 and CYP2D6 inhibitor among SSRIs. Any co-administered medication metabolized by these enzymes (LDA via 2D6; several antihistamines via 2D6) will have significantly elevated plasma levels — check CYP interactions before combining.

3.5 How fluvoxamine combines with other medications

Fluvoxamine + TUDCA/4-phenylbutyrate both work → converging evidence for ER stress.
Fluvoxamine + mitochondrial supplements both work → impaired ER-mitochondrial calcium transfer plus a downstream mitochondrial substrate limitation.
Fluvoxamine does not work + TUDCA works → a TUDCA-responsive UPR branch is dominant, not the S1R-mediated arm.

3.6 Compendium

4 Glycyrrhizin (Licorice Root)

Glycyrrhizin directly neutralizes HMGB1 — a damage-associated molecular pattern (DAMP) released during cellular stress that drives sterile inflammation. It probes whether HMGB1-mediated DAMP signaling contributes to post-exertional malaise (PEM).

4.1 If glycyrrhizin works

Finding: HMGB1 is a causal PEM mediator

If it reduces post-exertional HMGB1 and PEM together, HMGB1-driven DAMP signaling was contributing causally to PEM.

Certainty: Low to Medium.
Does NOT tell us: what triggers HMGB1 release in the first place.
Action: Supports measuring post-exertional HMGB1 as a biomarker; targets DAMP signaling.
Level of action: Partial root cause.

4.2 What a positive response does NOT reveal

What triggers HMGB1 release (oxidative stress, cell death, other DAMPs upstream).
Whether HMGB1 is the sole or one of several PEM mediators.

4.3 If glycyrrhizin does NOT work

HMGB1 may not be the dominant DAMP.
PEM may be driven by other mechanisms.
Glycyrrhizin may not reach the compartment where HMGB1 is active.

4.4 Key caveat

Pseudoaldosteronism (hypertension, hypokalemia, edema) limits use to short trials — a maximum of 4–6 weeks without monitoring. Monitor blood pressure and potassium.

4.5 How glycyrrhizin combines with other medications

Glycyrrhizin + NAC both work → an oxidative-stress → DAMP-release cascade.
Glycyrrhizin + dornase alfa both work → DAMP-driven inflammation from both HMGB1 and NET components.
Glycyrrhizin reduces post-exertional HMGB1 but PEM persists → HMGB1 is one PEM component; other mechanisms also contribute.

4.6 Compendium

5 Low-Dose IL-2

Low-dose interleukin-2 selectively expands regulatory T cells (Tregs), the immune cells that suppress autoreactive responses. It probes whether Treg deficiency permits autoantibody production — if restoring Tregs reduces autoantibodies, their deficiency was permissive.

5.1 If low-dose IL-2 works

Finding: Treg deficiency was permissive (if Tregs expand AND autoantibodies fall)

If Tregs expand and autoantibody titers fall, an inadequate regulatory-T-cell population had been permitting autoantibody production; restoring it suppressed that production.

Certainty: Low.
Does NOT tell us: why Tregs were deficient in the first place.
Action: Supports Treg deficiency as a target; requires Treg frequency measurement to confirm.
Level of action: Partial root cause.

Finding: Treg-independent autoantibody production (if Tregs expand but autoantibodies do not fall)

If Tregs expand but autoantibodies do not fall, autoantibody production is Treg-independent — driven by autonomous B cells or plasma cells that no longer require permissive conditions.

Certainty: Low — inferential from the dissociation.
Does NOT tell us: which B-cell/plasma-cell population is autonomous.
Action: Redirects toward B-cell-directed therapy rather than Treg support.
Level of action: Partial root cause (diagnostic redirection).

5.2 What a positive response does NOT reveal

Why Tregs were deficient.
Whether the autoantibodies are pathogenic or bystander markers.

5.3 If low-dose IL-2 does NOT work

Tregs may fail to expand (impaired IL-2 receptor signaling).
Treg expansion may be suppressed by inflammatory cytokines.
Treg deficiency may not be contributing.

5.4 Key caveat

Low-dose IL-2 is not standard-of-care and is available only in research protocols. Treg frequency (CD4+CD25+FoxP3+) must be measured before and after to confirm a biological effect.

5.5 How low-dose IL-2 combines with other medications

Low-dose IL-2 + rituximab both work → Treg expansion suppresses new autoantibody production while rituximab eliminates existing B cells.
Low-dose IL-2 works + rituximab does not sustain response → Treg deficiency is driving continuous B-cell stimulation.

5.6 Compendium

6 Methyl-Donor Support (SAMe, Methylfolate, Methylcobalamin, Choline, Betaine)

Methyl donors supply the substrate for DNA and protein methylation. They probe whether HSAT2 pericentromeric satellite-repeat derepression contributes to disease maintenance via loss of DNA methylation — restoring methyl availability could re-silence these repeats. Methyl donors also have well-established independent roles in homocysteine handling and BH4/neurotransmitter synthesis.

6.1 If methyl donors work

Finding: Epigenetic re-silencing achievable (if HSAT2 expression decreases)

If HSAT2 expression falls, the methylation machinery can restore silencing of the derepressed repeats — loss of DNA methylation was contributing.

Certainty: Low — the HSAT2 cascade is anchored in a single Ewing sarcoma preprint.
Does NOT tell us: whether HSAT2 derepression was driving symptoms or a bystander.
Action: Supports methylation support; measure HSAT2 where feasible.
Level of action: Partial root cause.

Finding: Independent benefit (if HSAT2 does not decrease but clinical improvement occurs)

If symptoms improve without a fall in HSAT2, the benefit likely comes from homocysteine reduction or BH4/neurotransmitter support rather than from re-silencing.

Certainty: Low to Medium — the independent pathways are better established than HSAT2.
Does NOT tell us: which independent pathway (homocysteine vs. BH4) drove the improvement.
Action: Supports methyl-donor support on its established rationale; check homocysteine.
Level of action: Partial root cause.

6.2 What a positive response does NOT reveal

Whether the benefit is epigenetic (HSAT2 re-silencing) or metabolic (homocysteine/BH4).
Whether HSAT2 derepression is causal in ME/CFS at all.

6.3 If methyl donors do NOT work

HSAT2 may not be a dominant mechanism.
The methylation machinery may be enzymatically impaired (e.g., MTHFR variants).
SAMe can cause irritability or anxiety in some ME/CFS patients, limiting tolerability.

6.4 Key caveat

HSAT2 as an ME/CFS mechanism derives from a single Ewing sarcoma preprint — a highly speculative extrapolation. Methyl donors have independent, better-established rationale (homocysteine, BH4, neurotransmitter synthesis). Test MTHFR and homocysteine before supplementing.

6.5 How methyl donors combine with other medications

Methyl donors + NAC both work → combined oxidative stress and methylation depletion (HSAT2 can be driven both by ROS via HSF1 and by methylation loss).
B6/B12/folate help + B3/NAD+ also helps → multiple B-vitamin pool depletions are co-present.

6.6 Compendium

The full pharmacodiagnostic entries — including mechanism-exclusion logic, dose-specific side-effect diagnostic patterns, combination diagnostics, and worsening risk profiles — are at Mechanistic Cascade Tracing: From Hypothesis to Clinical Probe (sec-12, SAMe entry and Vitamin B12 entry).

7 TUDCA / 4-Phenylbutyrate

TUDCA and 4-phenylbutyrate are chemical chaperones that reduce endoplasmic reticulum (ER) stress by stabilizing protein folding and inhibiting the unfolded protein response (UPR). They probe whether ER stress is a significant disease amplifier.

7.1 If TUDCA/4-PBA work

Finding: ER stress is a significant amplifier

Improvement means accumulated ER stress was amplifying the disease process; stabilizing protein folding and calming the UPR helped.

Certainty: Low — no ME/CFS data.
Does NOT tell us: which UPR branch is involved or what triggers the ER stress.
Action: Supports ER stress as a contributor; use the CNS-penetrant form where central effects are sought.
Level of action: Partial root cause.

7.2 What a positive response does NOT reveal

Which UPR branch (PERK, IRE1, ATF6) is driving the stress.
The upstream trigger of ER stress.

7.3 If TUDCA/4-PBA do NOT work

ER stress may not be a dominant mechanism.
ER stress may be present but driving a pathway these chaperones do not address (e.g., the PERK→eIF2α→ATF4 branch is not inhibited by TUDCA).
A formulation issue — choose TUDCA over UDCA for CNS penetration.

7.4 Key caveat

4-Phenylbutyrate is approved for urea cycle disorders and TUDCA for cholestatic liver disease — both are off-label for ME/CFS with no clinical trial data. TUDCA has better CNS penetration than UDCA. 4-PBA has high sodium content, relevant in hypertensive or sodium-sensitive patients.

7.5 How TUDCA/4-PBA combine with other medications

TUDCA/4-PBA + fluvoxamine both work → converging evidence for ER stress.
TUDCA works + fluvoxamine does not → a TUDCA-responsive UPR branch is dominant, not the S1R-mediated calcium arm.
TUDCA + mitochondrial supplements both work → impaired ER-mitochondrial calcium transfer plus a downstream mitochondrial substrate limitation co-present.

7.6 Compendium

8 tVNS (transcutaneous Vagal Nerve Stimulation)

Transcutaneous vagal nerve stimulation stimulates the auricular branch of the vagus nerve, enhancing parasympathetic tone. It probes whether vagal deficiency contributes to inflammation and autonomic dysfunction, and — via its sham comparison — whether muscarinic receptor blockade is present.

8.1 If tVNS works

Finding: Vagal deficiency contributed to inflammation and autonomic dysfunction

Improvement means insufficient parasympathetic (vagal) tone was permitting inflammation and autonomic imbalance; enhancing it helped, consistent with the cholinergic anti-inflammatory pathway.

Certainty: Low — sham-controlled post-COVID trials were null.
Does NOT tell us: whether the deficiency is in vagal output or in downstream receptor responsiveness.
Action: Supports vagal augmentation as a contributor to test further.
Level of action: Partial root cause.

Finding: Muscarinic receptor blockade (if sham outperforms active)

If the sham condition outperforms active stimulation, GPCR autoantibodies may be blocking muscarinic receptors, preventing acetylcholine signaling — so delivering more vagal signal cannot help because the receiving receptors are blocked.

Certainty: Low — inferential; requires autoantibody testing to confirm.
Does NOT tell us: which muscarinic subtype is blocked or the autoantibody titer.
Action: Becomes relevant to test for muscarinic (GPCR) autoantibodies.
Level of action: Partial root cause (if autoantibody-mediated).

8.2 What a positive response does NOT reveal

Whether the benefit reflects vagal augmentation or a non-specific relaxation effect.
The upstream cause of vagal deficiency.

8.3 If tVNS does NOT work

Vagal nerve function may itself be insufficient to respond.
Downstream muscarinic receptors may be blocked by autoantibodies.
Electrode placement varies and may not deliver adequate stimulation.
Null post-COVID trials may not generalize to ME/CFS, but they lower prior confidence.

8.4 Key caveat

tVNS requires consistent stimulation parameters; home devices vary in output, and benefits typically require weeks of daily use before they can be assessed.

8.5 How tVNS combines with other medications

tVNS + pyridostigmine both work → converging vagal/cholinergic augmentation strategies.
tVNS works + pyridostigmine does not → tVNS provides a pre-ganglionic signal that pyridostigmine cannot.
tVNS sham beats active + LDN works → autoantibody-blocked muscarinic receptors coexist with neuroinflammation.